Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia

Eur J Pharmacol. 2011 Aug 16;664(1-3):45-53. doi: 10.1016/j.ejphar.2011.04.059. Epub 2011 May 7.

Abstract

Resveratrol has been purported to modify risk factors for obesity and cardiovascular disease. We sought to examine the effects of resveratrol in a porcine model of metabolic syndrome and chronic myocardial ischemia. Yorkshire swine were fed either a normal diet (control), a high cholesterol diet (HCD), or a high cholesterol diet with supplemental resveratrol (HCD-R; 100mg/kg/day) for 11 weeks. After 4 weeks of diet modification a baseline cardiovascular MRI was performed and an ameroid constrictor was placed on the left circumflex coronary artery of each animal to induce chronic myocardial ischemia. At 7 weeks, a second cardiovascular MRI was performed and swine were sacrificed and myocardial tissue harvested. Resveratrol supplementation resulted in lower body mass indices, serum cholesterol, and C-reactive protein levels, improved glucose tolerance and endothelial function, and favorably augmented signaling pathways associated with myocardial metabolism. Interestingly, serum tumor necrosis factor-α levels were not influenced by resveratrol treatment. Immunoblotting for markers of metabolism demonstrated that insulin receptor substrate-1, glucose transporters 1 and 4, and phospho-AMPK were increased in the HCD-R group. Peroxisome proliferator-activated receptor γ and retinol binding protein 4 were downregulated in the HCD-R group as compared to the HCD group. Myocardial perfusion and function at rest as assessed with magnetic resonance imaging were not different between groups. By favorably influencing risk factors, resveratrol may decrease the burden of chronic metabolic disease and improve cardiovascular health.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Cholesterol / blood
  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / physiopathology
  • Diet / adverse effects
  • Dietary Supplements
  • Fatty Acids, Nonesterified / blood
  • Gene Expression Regulation / drug effects
  • Glucose Tolerance Test
  • Glucose Transporter Type 4 / metabolism
  • Heart / drug effects
  • Heart / physiopathology
  • Inflammation / metabolism
  • Insulin / blood
  • Magnetic Resonance Imaging
  • Metabolic Syndrome / complications*
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / metabolism
  • Metabolic Syndrome / physiopathology
  • Microvessels / drug effects
  • Microvessels / physiopathology
  • Muscle Cells / drug effects
  • Muscle Cells / metabolism
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / metabolism
  • Myocardial Ischemia / physiopathology
  • Oxidation-Reduction / drug effects
  • Protein Transport / drug effects
  • Resveratrol
  • Risk Factors
  • Stilbenes / pharmacology*
  • Stilbenes / therapeutic use
  • Swine

Substances

  • Biomarkers
  • Fatty Acids, Nonesterified
  • Glucose Transporter Type 4
  • Insulin
  • Stilbenes
  • Cholesterol
  • Resveratrol